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N
eurodevelopmental disorder (ND) defines
as failure to attain a normal neurological
function that a child must have. It is caused
by brain defect which occurs early in the
brain development process. The initial insult of this
disorder may occur in the prenatal, perinatal, or
postnatal period.1-3   One of the screening tools used
to asses ND risks in infants or children aged 3-24
months is BINS (Bayley Infant Neurodevelopmental
Screener) score. The accuracy of BINS score assessment
on each group is 75-86%.4-6 The incidence of ND cases
is increasing due to the  impact of improvements in
neonatal care and the development in new diagnostic
tools. There were approximately 20-30% cases of neuro-
developmental disorder in Department of Child
Health.1 One of the causes of ND that is commonly
found in perinatal period is hyperbilirubinemia,4,5
defined as serum total bilirubin level (STB) >5 mg/dL
(86 ìmol/L).6  Hyperbilirubinemia can cause brain
“intoxication” which results in permanent neuron
ABSTRACT
Background Neurodevelopmental disorder (ND) is defined as
failure to attain normal neurological function. Indirect bilirubin
has essential role because its neurotoxic properties. Neonates with
hyperbilirubinemia carry the risk to develop ND.
Objective To determine the association between neonatal indirect
hyperbilirubinemia and the risk of ND.
Methods Neonates with indirect serum bilirubin (SIB) level >10
mg/dL, admitted in the period of October 2004-August 2005, were
included in this study. They were followed-up and screened using
Bayley Infant Neurodevelopmental Screener (BINS) at three, six
and nine months. Mann-Whitney test was used to test the
hypothesis.
Results Forty-eight neonates were included in the study. Mean
SIB level of subjects with ND risk was 20.5 mg/dL (SD=6.06;
p<0.001). Mean SIB level of subjects who developed ND at three,
six and nine months was 31.6 mg/dL (SD=4.02), 18.4 mg/dL
(SD=2.92) and 18.4 mg/dL (SD=5.41), respectively. There was
statistically significant correlation  between SIB level and ND
risk (R=+0.64; P<0.001). There was also statistically significant
correlation between SIB level and the onset of ND (R=-0.63;
P< 0.001).
Conclusion There is a correlation between neonatal SIB level
and the risk of ND in babies. [Paediatr Indones 2008;48:93-
98].
Keywords: neonates, hyperbilirubinemia, neuro-
developmental disorder
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damage. In this regard, the role of indirect bilirubin is
essential because its neurotoxic properties. Indirect
bilirubin, in in-vitro and in-vivo studies, has been shown
to cross blood brain barrier by diffusion in high
concentration.7-9 In general, a neonate is considered
“impaired” when serum indirect bilirubin (SIB) level
>10 mg/dL.9  A neonate with hyperbilirubinemia leads
to the risk of early neonatal death or survived with a
sequel namely  ND in the future.4-6
Recently  some  reports pointed out that
hyperbilirubinemia in term babies has the potential
to cause ND.10,11  For this reason, this study was carried
out to determine the correlation between neonatal
indirect hyperbilirubinemia and the risk of ND.
Methods
This prospective cohort study examined neonates with
indirect hyperbilirubinemia who were admitted to the
Special Care (Level II) in Dr. Kariadi Hospital,
Semarang, in October 2004 to August 2005. The
inclusion criteria were term babies, born spontaneously
with birth weight > 2500 g, and had indirect serum
bilirubin level >10 mg/dl, and the parents gave
informed consent to participate. We excluded babies
with history of diseases which could impair neuro-
logical functions (meningitis, encephalitis, cerebral
palsy), those who suffered from severe asphyxia at
birth, and those with Down syndrome and/or other
congenital abnormalities. The subjects were chosen
by consecutive sampling method.
After selecting the neonates, clinical and laboratory
examination (especially higher SIB level) were done
during nursing care. After full recovery, subjects
subsequently underwent screening test with Bayley Infant
Neurodevelopmental Screener (BINS) at the age of
three, six and nine months to detect the risk of ND.
We presented data in frequency distribution and
percentage, or with standard deviations. We performed
Mann Whitney test to compare the SIB levels of
subjects with and without ND risk. Level of
significance was set at P < 0.05 with 95% confidence
interval.
Results
Characteristics of study subjects
Forty-eight neonates were included in this study with
mean age of 3.9 (SD=1.12) days. The characteristics
of study subjects were shown in Table 1.
Infection was defined based on bacteria found
in culture of body specimens. The treatments for
hyperbilirubinaemia were as follows: 18 (38%) subjects
received phototherapy, 8 (17%) received photo-
therapy and exchange transfusion, and 22 (46%)
received no therapy. For the purpose of further data
analyses, the subjects were categorized as receiving
phototherapy with or without exchange transfusion
(with therapy) which consisted of 26 subjects (54%)
and subjects without phototherapy or exchange
transfusion (without therapy) which consisted of 22
subjects (46%). (Table 2)
Neurological  development measurement
The results of neonatal neurodevelopmental testing
by BINS until 9 months of age showed that 29 (60%)
subjects had no risk for ND (low BINS score), and 19
(40%) subjects had moderate ND risk (moderate BINS
score). From these 19 subjects, three had their ND
risk detected at three months, 12 subjects at six
months, and four subjects at nine months.
Kaplan Meier test revealed that the mean
occurrence of ND risk in subjects with history of
neonatal hyperbilirubinemia was at 8 months.
Table 2. Neonatal bilirubin levels of subjects
Variables Mean (SD) Minimum Maximum
STB (mg/dL) 16.7 (5.87) 10.21 38.00
SIB  (mg/dL) 16.1 (5.66)  10.11 35.50
Table 1. Characteristics of study subjects
Variables n (%)
Sex
- boys 26 (54%)
- girls 22 (46%)
Infection 27 (56%)




- without therapy 22 (46%)
- with therapy 26 (54%)
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Plasma bilirubin level and eurodevelopmental
disorder (ND)
The levels of STB and SIB in subjects with and without
ND are presented in Table 3.
Results of BINS score assessments were categori-
zed into three different subgroups i.e., low, moderate,
and high risk groups. If subjects were defined to have
high risk, meticulous investigations were performed
to find any manifestations of ND. Otherwise, if subjects
were classified to have moderate risk, examination
then repeated one month afterwards. But if subjects
were only having low risk, no ND was discovered.
Table 3 shows that the neonatal STB level of
subjects with ND risk (21.1 mg/dl [SD=6.64]) is
significantly higher than subjects without ND risk
[13.8 mg/dL (SD=2.76)].
The same findings were also found for the
neonatal SIB level, where subjects with ND risk had
significantly higher level (20.5 mg/dl [SD=6.06]) than
subjects without ND risk (13.2 mg/dl [SD=2.90]).
Table 3 showed that either STB or SIB on subjects
who was exposed to risks in developing ND was >20
mg/dl, and was significantly higher than subjects
without risk of developing ND.
Correlation test revealed moderate correlation
between  neonatal STB level and ND risk (r = +0.62;
P<0.001). Moderate correlation  was also found
between neonatal SIB level and  ND risk (r = +0.64;
P<0.001), showing that the higher STB or SIB level,
the higher  risk for developing ND in the future.
The comparison of neonatal STB and SIB level
based on the occurrence of ND is shown in Table 4.
The same observation was also found in SIB
level, where subjects with earlier occurrence of ND
risk (three  months old) have significantly higher SIB
level than subjects with later occurrence of ND risk
(six months old; P=0.004 or nine months old;
P=0.05). There was also no statistically significant
difference between neonatal SIB level of subjects who
developed ND risk at six months and nine months
old (P=0.9). The comparison of neonatal STB and
SIB levels based on the development of ND risk is
also shown in Figure 1.
Spearman correlation test showed moderate
correlation between STB level and the onset of ND
(correlation coefficient -0.63; P<0.001). The same
correlation was also found for SIB level (correlation
coefficient –0,63 ; P<0,001). This means that the
higher the STB/ SIB level, the earlier will be the onset
of ND.
Table 5 shows variables such as SIB >14.68 mg/
dl, infection, and subjects who was not given therapy
for hyperbilirubinemia were all risk factors for
developing ND in infants. Conversely, asphyxia is
protective factor for ND. Nevertheless, from
subsequent analysis subjects suffered from asphyxia
tend to have SIB lower than subjects who never had
history of asphyxia.
Discussion
From the 48 subjects in this study, the male to female
ratio was 1.18:1. Earlier studies show that the sex
proportion of subjects with hyperbilirubinemia varies;
Table 4. Comparison of STB and SIB level based on the
occurrence of ND
Age (months) STB (Mean/SD) SIB (Mean/SD)
3 months (n=3) 33,6 (SD=5.10) 31,6 (SD=4.02)
6 months (n=12) 18,7 (SD=2.90) 18,4 (SD=2.92)
9 months (n=4) 18,8 (SD=5.43) 18,4 (SD=5.41)
Serum total bilirubin level
- 3 vs 6 months: P=0.004
- 3 vs 9 months: P=0.05
- 6 vs 9 months: P=0.9
Serum indirect bilirubin level
- 3 vs 6 months: P=0.004
- 3 vs 9 months: P=0.05
- 6 vs 9 months: P=0.9
Table 3. The association of neonatal hyperbilirubinemia and ND risk
         Neurodevelopmental disorder risk p*
Variables Mild Moderate and Severe
Mean SD Mean SD
Total bilirubin 13.8 (2.76) 21.1 (6.64) < 0.001
Indirect bilirubin 13.2 (2.90) 20.5 (6.06) < 0.001
* Mann-Whitney test
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in general sex has no influence on the occurrence of
hyperbilirubinemia or ND.12
The mean age of the subjects when hyperbili-
rubinemia developed was 3.9 days. Porter reported that
60% of term neonates will have neonatal jaundice
within the first week of life, which has the potential
to become hyperbilirubinemia. It is also reported that
hyperbilirubinemia with STB level > 15 mg/dl mostly
occur at 25-48 hours, STB > 18 mg/dl at 49-72 hours,
and STB > 20 mg/dl at > 72 hours of age.6 In this
study, the onset of highest hyperbilirubinemia cannot
be determined precisely. This is because the
assumption of peak level was based on subjective
Kramer method, before the examination of serum
bilirubin level. Spearman correlation test, showed that
higher STB/ SIB level will cause earlier onset of ND.
Table 5. Risk factors among neonates with risks of developing ND in infants
                            ND
Variable Absent Present RR (95% CI) P
n (%) n (%)
Serum Indirect Bilirubin :
- >14,68 23 (89%) 3 (12%)
- <14,68 6 (27%) 16 (72%) 6.3 (2.1;18.8) < 0.001
Infection:
- Yes 19 (91%) 2 (10%)
- No 10 (37%) 17 (63%) 6.6 (1.7;25.5) < 0.001
Acidosis :
- Yes 23 (66%) 12 (34%)
- No 6 (46%) 7 (54%) 1.5 (0.80;3.1) 0.2
Asphyxia:
- Yes 9 (43%) 12 (57%)
- No 20 (74%) 7 (26%) 0.5 (0.2;0.9) 0.03
Hypoglicemia :
- Yes 26 (61%) 17 (40%)
- No 3 (60%) 2 (40%) 1.0 (0.3;3.1) 0.98
Therapy :
- Without therapy 20 (91%) 2 (9%)
- with therapy 9 (35%) 17 (65%) 7.2 (1.9;27.80 < 0.001

































The onset of neurodevelopmentalal
disorder (months)
The onset of neurodevelopmentalal
disorder (months)
0.00












Baginda Hutahaean et al: Neurodevelopment disorder in babies with hyperbilirubinemia
Paediatr Indones, Vol. 48, No. 2, March 2008 • 97
In this study, we found 40% subjects with ND
risk, and 60% subjects without ND risk. The mean
STB level of subjects with ND risk was 21.1 mg/dl,
and their mean SIB level was 20.5 mg/dL. The mean
onset of ND was eight months. Study by Yilmaz
reported that subjects aged 10-72 months with history
of neonatal hyperbilirubinemia (peak STB level < 20
mg/dl) did not show neurological abnormalities.
However, 9.3% subjects with peak BTS level 20-23.9
mg/dL developed sight disconjugation, and subjects
with peak BTS level > 24 mg/dl developed neuro-
logical disorders.13  Newman and Klebanoff  found
significant correlation  between neonatal BTS level
> 20 mg/dl and abnormal neurological findings, but
they didn’t find significant correlation  with abnormal
neurological findings at 7 years.14  Another study on
the population from the Collaborative Perinatal
Project concludes that there are no consistent events
which support neurological abnormalities in children
with history of neonatal hyperbilirubinemia > 20 mg/
dl on follow up at seven years old.12
In several studies on the correlations of hyper-
bilirubinemia and ND, the age at the onset of ND could
be in the range of four months to 14 years. Vohr and
Paludetto also confirmed this correlation during
neonatal period by using the Brazelton Neonatal
Behavioral Assessment Scale (BNBAS).15,16
This study also reports the risk factors for
disruption of blood brain barrier, including infection
(56%), asphyxia (56%), acidosis (27%) and hypo-
glycemia (10%). One of the functions of blood brain
barrier is to regulate the influx of bilirubin into the
brain. Free indirect bilirubin (FIB) has the ability to
penetrate intact blood brain barier and then infiltrate
the membrane cell of the neuron. Assessment of FIB
serum concentration still can not be done in most of
large hospitals in Indonesia. This partially explains
why not all neonates with hyperbiluribunemia will
develop ND, and ND can also develop in subjects
with “low” hyperbilirubinemia concentration.3,7,17,18
In addition, there were 54% subjects who received
phototherapy with or without exchange transfusion.
Phototherapy and exchange transfusion are essential
methods to prevent the occurrence or worsening of
neurodevelopmental disorder (ND).
Asphyxia, particularly severe asphyxia, results
in neuron injury due to brain ischemia. Acidosis
caused by hypoxia results in deficit of oxygen supply
which subsequently generates anaerobe glycolysis,
diminishes ATP and increases lactate production.
Severe hypoglycaemia in neonates reduces brain
electrical activity, then destructs neuron membrane,
escalates glutamate production, consequently causes
necrosis of the neuron.19,20
Up until now, there are no clear cut criteria on
what level of bilirubin will cause ND. This question
cannot be answered simply by numbers, because serum
bilirubin level is only a part of many risk factors for
the development of ND. However, based on previous
studies, in general we can conclude that mean serum
total bilirubin level > 20 mg/dL has the potential to
cause ND, although STB level < 20 mg/dl can also
cause ND, especially if accompanied with risk factors.
Therefore, every baby must be individually evaluated
based on their bilirubin level and the presence of risk
factor(s).10
Limitations of the present study is that we could
not determine the highest value of hyperbilirubinemia
precisely. This is due to the determination of the
utmost point of bilirubin serum was estimated by
Kramer method which is a subjective examination
before we measured the actual value of serum bilirubin.
In conclusion, our study the mean STB and SIB
levels in subjects with ND risk are significantly higher
than in subjects without ND risk. There is moderate
correlation  between neonatal STB and SIB level with
the risk of ND, significant correlation between neo-
natal STB/SIB level and the onset of ND.  Neonatal
infection, indirect serum bilirubin concentration
>14.68 mg/dl, and no hyperbilirubinemia therapy
were all factors that lead infants suffer from hyperbi-
lirubinemia to develop ND.
References
1. Saharso D. Gangguan perkembangan neurologis. In:
Firmansyah A, Sastroasmoro S, Trihono PP, editors. Naskah
lengkap KONIKA XI. Jakarta: IDAI Pusat; 1999. p. 571-88.
2. Njiokiktjien C, Panggabean R, Hartono B. Masalah-masalah
dalam perkembangan psikomotor. Semarang: Wonodri Offset
Ltd; 2003. p. 1-55.
3. Kliegman RM. Jaundice and hyperbilirubinemia in the
newborn. In: Nelson WE, Behrman RE, Kliegman R, Arvin
AM, editors. Nelson textbook of pediatrics. 16th ed.
Philadelphia: WB Saunders Co; 2000. p. 610-6.
